Iovance Stock Surges 199.53% to 271st in Market Rankings as FDA Accepts Lifileucel BLA

On July 23, 2025, Iovance's trading volume reached 4.40 billion, marking a significant increase of 199.53% compared to the previous day. This surge placed Iovance at the 271st position in the day's stock market rankings. Iovance(IOVA) has been on a three-day winning streak, with a cumulative increase of 78.03% over the past three days.

Iovance Biotherapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its lead product candidate, Lifileucel, for the treatment of metastatic melanoma. This acceptance is a significant milestone for the company, as it brings Lifileucel one step closer to potential approval and commercialization.

In addition to the FDA's acceptance of the BLA, Iovance has also reported positive interim data from its ongoing Phase 2 trial of Lifileucel in patients with metastatic melanoma. The data showed that Lifileucel demonstrated a durable response rate of 48% in patients who had previously received anti-PD-1 therapy. This is a promising result, as it suggests that Lifileucel may be an effective treatment option for patients who have not responded to other therapies.

Iovance's stock price has been volatile in recent months, with the company's shares experiencing significant fluctuations. However, the recent news regarding the FDA's acceptance of the BLA for Lifileucel and the positive interim data from the Phase 2 trial have provided a boost to the company's stock price, with investors expressing optimism about the potential of Lifileucel as a treatment for metastatic melanoma.